strategic partners & surgeons only · no spam · briefings on request
▼ The market
ANKLE FRACTURE ◂ FIBULAR NAILING ◂ SYNDESMOSIS REPAIR ◂ LOWER EXTREMITY TRAUMA ◂ 510(K) PATHWAY ◂ EARLY IN · EARLY OUT ◂ MALVERN PA ◂ANKLE FRACTURE ◂ FIBULAR NAILING ◂ SYNDESMOSIS REPAIR ◂ LOWER EXTREMITY TRAUMA ◂ 510(K) PATHWAY ◂ EARLY IN · EARLY OUT ◂ MALVERN PA ◂
// 01 — The Trauma Stack
where we sit.
A meaningful slice of a $4.7B US market.
Crossover is targeting two of the most clinically important — and most under-innovated — indications inside the US trauma fixation stack. Working backward from the top:
US Trauma Fixation Devices
All segments, internal + external
~$4.7B
Internal Fixation (Plates · Nails · Screws)
Internal fixators dominate at ~65% of US trauma fixation
~$3.4B
Foot & Ankle / Lower Extremity Distal
Ankle trauma is the largest distal lower-extremity segment
~$1.5B
Crossover Target — Fibular + Syndesmosis
The two indications around which the platform is built
~$650M+
Sources: GM Insights US Trauma Fixation 2024 ($4.7B → $6.2B by 2034) · iData Research Trauma MedSuite · Fact.MR Syndesmosis Repair Forecast · Crossover internal segment build-up. Figures are top-down estimates; not all market reports break out distal lower-extremity uniformly.
// 02 — Three Indications, One Anatomy
the wedge.
High volume. Low innovation.
Ankle fracture is the entry point. Fibular nailing and syndesmosis repair are the two specific indications inside it where the clinical evidence — and the competitive activity — say the category is moving.
A — THE SEGMENT
Ankle Fracture
~1 in 10 of all fractures
US INCIDENCE~585Kper year
SURGICAL~25%require operative fixation
DISTAL FIBULA~9%of all fractures involve the distal fibula
PEAK COHORT50–54age group, with secondary peak in 65+
MECHANISM54%caused by simple falls — scales with aging
▸ THE OPENING
The largest under-innovated lower-extremity fracture category. Two-thirds of operative ankle fractures are isolated fibular / lateral malleolus — the exact bone Crossover is built around.
SRC: NEISS · J Foot & Ankle Surgery (Scheer 2020) · Podiatry Today · UK epidemiology data
B — THE INDICATION
Fibular Nailing
vs. lateral plating · the shift
WOUND INFXNp = 0.002significantly fewer vs. plate (RCT, elderly)
ORIF COMPLIC.~33%complication rate in open ankle, elderly cohort
REOP RATE~19%following ORIF in same series
FUNCTIONAL=equivalent outcomes vs. plate at 1 year
BIOMECH.↑ loadhigher load-to-failure than plate in cadaveric studies
▸ THE OPENING
Strategics have validated the category but the implant generation is still early. Multiple strategics have launched or entered the segment in 2023–2024. The race is for the second-generation platform.
SRC: White et al. Bone & Joint J · JBJS Am 2022 (younger pts) · Walsh et al. meta-analysis · Cureus systematic review 2025
Suture button adoption has already proven the market will pay for better, not cheaper. The next move is reproducibility — taking the variability out of how that tension is applied.
The last 24 months have produced more product activity in fibular nailing and syndesmosis fixation than the prior decade combined. The majors believe the category is moving. The window for the next generation is open.
▸ 2023
ACME Ortho
Launched their next-gen fibular nailing platform — marketed as a category-defining architecture, signaling the majors are now investing here.
▸ EARLY 2024
BoneCorp Medical
Entered the segment with the integrated nail system for ankle fracture fixation. A top-tier trauma player now actively building a fibular nail line.
▸ LATE 2024
TraumaCo Industries
Received 510(k) clearance for the tensioned suture button system — first suture-based fixation product in their trauma portfolio.
“When the strategics start launching, the category is no longer the question. The architecture is. Crossover is being built for the next architectural step — not the one that just happened.”
// 04 — The Stagnation
three decades.
How long has it been since the last real shift?
Trauma fixation of the lateral malleolus has been incrementally refined for thirty years. The implant placed today shares its core architecture with hardware designed before most surgical residents were born.
1990s
Lateral plating becomes standard of care
2000s
Pre-contoured anatomic plates
2010s
Suture button proves dynamic fixation works
2020s
First-gen fibular nails enter the market — minor iteration
2027+
A platform rebuild
// 05 — The Platform
stealth mode.
Two systems. One bone. Both quiet.
We’re not ready to talk about the implants. We are ready to talk about why they exist — and who needs to know.
DOC-001 / CLASS II / 510(k) TRACK
Implant System A
intramedullary · load-sharing
REDACTED
DOC-002 / CLASS II / 510(k) TRACK
Implant System B
tensioned · reproducible
REDACTED
Detailed briefings available under NDA for qualified strategics and clinical advisors
// 06 — The Team
the operators.
Built and exited trauma companies before.
A focused, hands-on team — small by design — backed by senior clinical advisors at the top of orthopedic trauma and foot/ankle surgery.
CEO
Jeff O’Donnell Jr.
Chief Executive Officer · General Partner, Runway Healthcare
CTO
Bill Rhoda
Chief Technology Officer · General Partner, Runway Healthcare
Product
Kaileen Osisek
Product Manager
R&D
Mike Harper
Senior R&D Engineer
R&D
Caroline Ries
Associate Engineer
SM
Samir Mehta, MD
University of Pennsylvania · Orthopaedic Trauma
trauma · fibular fixation
LS
Lew Schon, MD
NYU Langone · Mercy Medical Center
foot & ankle · innovation
A Runway Healthcare Company
Engineered for Acquisition
Early In · Early Out — Concept through 510(k) clearance
Crossover is selectively engaging strategic partners, surgeon advisors, and investors ahead of clearance. Pick the door that fits.
For Strategic Acquirers
Partnership Briefing
If you operate in lower-extremity orthopedics and want a private look at our regulatory line of sight, IP position, and acquisition timeline, we’ll schedule a confidential briefing under NDA.
